NCT03168659 CardioFocus HeartLight Post-Approval Study
| NCT ID | NCT03168659 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CardioFocus |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2017-06-16 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2017-06-16 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a post-approval study to evaluate the clinical outcomes in a cohort of participants treated during commercial use of the HeartLight System to confirm results of the previously conducted pivotal clinical study.
Eligibility Criteria
Inclusion Criteria: * 18 years or older * planned for catheter ablation due to symptomatic paroxysmal atrial fibrillation * failure of at least one anti-arrhythmic drug * others Exclusion Criteria: * overall good health as established by multiple criteria
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03168659 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03168659 currently recruiting?
Yes, NCT03168659 is actively recruiting participants. Contact the research team at lhausmann@cardiofocus.com for enrollment information.
Where is the NCT03168659 trial being conducted?
This trial is being conducted at Tucson, United States, Chicago, United States, New York, United States, Charlottesville, United States.
Who is sponsoring the NCT03168659 clinical trial?
NCT03168659 is sponsored by CardioFocus. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.